发布求助
文献互助 智能选刊 最新文献

Skinmed最新文献

筛选
英文 中文
A Particular Crusty Nodule of the Lip. 嘴唇上的特殊结节
Skinmed Pub Date : 2024-10-22 eCollection Date: 2024-01-01
Anissa Zaouak, Houda Hammami, Samy Fenniche
{"title":"A Particular Crusty Nodule of the Lip.","authors":"Anissa Zaouak, Houda Hammami, Samy Fenniche","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 5","pages":"366"},"PeriodicalIF":0.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unusual Eczematous Dermatitis on the Nipple and Areola in a Young Man with Clear Cell Acanthoma. 一名患有透明细胞棘皮瘤的年轻人的乳头和乳晕上出现异常湿疹性皮炎。
Skinmed Pub Date : 2024-10-22 eCollection Date: 2024-01-01
Denys Elizabeth Penaloza Daguer, Tatiana Fabiola Ordoñez, Luis Daniel Mazzuoccolo
{"title":"Unusual Eczematous Dermatitis on the Nipple and Areola in a Young Man with Clear Cell Acanthoma.","authors":"Denys Elizabeth Penaloza Daguer, Tatiana Fabiola Ordoñez, Luis Daniel Mazzuoccolo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 24-year-old man with no personal or family history of atopic dermatitis or psoriasis consulted our dermatology department with a desquamating reddish lesion on the left areola and nipple. The lesion, which had developed during the past 4 months, bled occasionally and was treated initially as dermatitis with a combination of topical corticoids and antimicrobials, resulting in partial lessening of the condition. An ultrasound of the skin revealed increased blood flow within the nipple thickening of the dermis. During physical examination, we observed a well-defined desquamating plaque with a slightly shiny surface on the left nipple and areola (Figure 1).</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 5","pages":"380-381"},"PeriodicalIF":0.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BIMZELX® (Bimekizumab-bkzx) Injection, for Subcutaneous Use. BIMZELX®（Bimekizumab-bkzx）注射液，皮下注射用。
Skinmed Pub Date : 2024-10-22 eCollection Date: 2024-01-01
Aditya K Gupta, Avantika Mann, Kimberly Vincent, William Abramovits
{"title":"BIMZELX<sup>®</sup> (Bimekizumab-bkzx) Injection, for Subcutaneous Use.","authors":"Aditya K Gupta, Avantika Mann, Kimberly Vincent, William Abramovits","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>BIMZELX<sup>®</sup> (bimekizumab-bkzx) injection, for subcutaneous use, was approved in October 2023 for moderate to severe plaque psoriasis in patients aged ≥18 years. In three phase 3, randomized, double-blind, vehicle, and comparator-controlled studies (Be Vivid, Be Ready, and Be Sure), bimekizumab was investigated for the treatment of plaque psoriasis. The primary efficacy end point was psoriatic area and severity index (PASI) 90 (patients with 90% improvement in PASI from baseline) and investigator's global assessment (IGA) score of 0 (clear skin)-1 (almost clear skin) as well as ≥2-point improvement from baseline at week 16. In the Be Vivid study, patients were randomized into the bimekizumab, placebo, and ustekinumab groups. PASI 90 score was achieved by 85% (273/321) in the bimekizumab group, 5% (4/83) in the placebo group, and 50% (81/163) in the ustekinumab group. IGA 0/1 score was achieved by 84% (270/321) in the bimekizumab group, 5% (4/83) in the placebo group, and 53% (87/163) in the ustekinumab group. In the Be Ready study, patients were randomized into bimekizumab and placebo groups. PASI 90 score was achieved by 91% (317/349) in the bimekizumab group and 1% (1/86) in the placebo group. IGA 0/1 score was achieved by 93% (323/349) in the bimekizumab group and 1% (1/86) in the placebo group. In the Be Sure study, patients were randomized into two bimekizumab groups (receiving different bimekizumab regimens) and one adalimumab group. PASI 90 score was achieved by 86.2% (275/319) in combined bimekizumab groups and 47.2% (75/159) in the adalimumab group. IGA 0/1 score was achieved by 85.3% (272/319) in combined bimekizumab groups and 57.2% (91/159) in the adalimumab group. Bimekizumab was well tolerated with no unexpected safety findings.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 5","pages":"370-374"},"PeriodicalIF":0.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Edward L. Keyes Resident Contest for Outstanding Case Reports. Edward L. Keyes 优秀病例报告住院医师竞赛。
Skinmed Pub Date : 2024-10-22 eCollection Date: 2024-01-01
Vesna M Petronic-Rosic
{"title":"Edward L. Keyes Resident Contest for Outstanding Case Reports.","authors":"Vesna M Petronic-Rosic","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 5","pages":"365"},"PeriodicalIF":0.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dermatoscopic Radial Rippling of Pigment: A Potential Indicator of Pigmented Bowen's Disease. 皮肤镜下色素的径向波纹：色素性鲍温氏病的潜在指标。
Skinmed Pub Date : 2024-10-22 eCollection Date: 2024-01-01
Melanie Ngo, Mark M Ash
{"title":"Dermatoscopic Radial Rippling of Pigment: A Potential Indicator of Pigmented Bowen's Disease.","authors":"Melanie Ngo, Mark M Ash","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Pigmented Bowen's disease (pBD) or pigmented squamous cell cancer <i>in situ</i> is uncommon, accounting for 1.67%-5.5% of Bowen's disease lesions. It resembles pigmented actinic keratosis, seborrheic keratosis, solar lentigo, atypical nevus, or melanoma, and is ruled out through biopsy. Pigmented Bowen's disease typically presents as an asymptomatic, flat or slightly raised, scaly, and well-delineated plaque that primarily affects individuals in their sixties. Risk factors include human papilloma virus infection, arsenic exposure, sun exposure, ionizing radiation, and trauma.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 5","pages":"393-395"},"PeriodicalIF":0.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The COVID-19-Associated Mucormycosis with Cutaneous Involvement. 与 COVID-19 相关的皮肤受累粘液瘤病。
Skinmed Pub Date : 2024-10-22 eCollection Date: 2024-01-01
Neel Prabha, Ripu Daman Arora, Anju George C, Archana B Wankhade, Ashish Kumar Gupta, Rakesh Kumar Gupta, Nitin M Nagarkar
{"title":"The COVID-19-Associated Mucormycosis with Cutaneous Involvement.","authors":"Neel Prabha, Ripu Daman Arora, Anju George C, Archana B Wankhade, Ashish Kumar Gupta, Rakesh Kumar Gupta, Nitin M Nagarkar","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Mucormycosis is an invasive fungal infection caused by fungi of the order Mucorales. During the coronavirus disease 2019 (COVID-19), a rise in the number of COVID-19-associated mucormycosis (CAM) patients was reported globally. Cutaneous mucormycosis is the third most common presentation of mucormycosis. It is classified as primary cutaneous and secondary cutaneous mucormycosis. The secondary form is more common than the primary cutaneous; however, most reports and case series in the literature are that of primary cutaneous mucormycosis. We accounted a case series of eight patients of CAM with secondary cutaneous mucormycosis.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 5","pages":"346-350"},"PeriodicalIF":0.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Light Therapy Modalities in the Management of Acne. 痤疮治疗中的光疗模式。
Skinmed Pub Date : 2024-10-22 eCollection Date: 2024-01-01
Sarah Friske, Tejas P Joshi, Jaime Tschen
{"title":"Light Therapy Modalities in the Management of Acne.","authors":"Sarah Friske, Tejas P Joshi, Jaime Tschen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Much like the update in the classification of the acne commensal from <i>Propionibacterium acnes (P. acnes)</i> to <i>Cutibacterium acnes (C. acnes)</i>, the treatment of acne has observed advances, augmenting topical and oral medications, including anti-microbial peptides, chemical peels, microencapsulated medications, and probiotics. The traditional paradigm of acne treatment has its limitations, such as skin irritation, photosensitivity, concern over antibiotic resistance, and regimen complexity. Given these challenges, discussing alternative options for acne treatment in detail is important. Light therapy, in particular, is an emerging modality that has transformed the landscape of acne management and thus merits additional discussion (Table 1).</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 5","pages":"328-330"},"PeriodicalIF":0.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CABTREOTM (Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide) Topical Gel. CABTREOTM（克林霉素磷酸酯、阿达帕林和过氧化苯甲酰）外用凝胶。
Skinmed Pub Date : 2024-10-22 eCollection Date: 2024-01-01
Aditya K Gupta, Avantika Mann, Kimberly Vincent, William Abramovits
{"title":"CABTREO<sup>TM</sup> (Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide) Topical Gel.","authors":"Aditya K Gupta, Avantika Mann, Kimberly Vincent, William Abramovits","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cabtreo<sup>TM</sup> (1.2% clindamycin phosphate, 0.15% adapalene, and 3.1% benzoyl peroxide) or IDP-126 topical gel was approved by the US Food and Drug Administration (FDA) in October 2023 for the treatment of moderate to severe acne vulgaris in patients aged ≥12 years. Its effectiveness and safety were evaluated in two phase 3 trials (Trial 1 and Trial 2). In both trials, subjects were randomized into two groups, one received IDP-126 gel and the other received vehicle gel. The primary efficacy end point was treatment success at week 12, defined as subjects achieving at least a 2-grade reduction from baseline in Evaluator's Global Severity Score (EGGS) and a final score ranging from 0 (clear) to 1 (almost clear) as well as reduced counts of inflammatory and non-inflammatory lesions. In Trial 1 (N = 183), treatment success was achieved in 49.6% (61/122) of subjects in the IDP-126 group versus 24.9% (15/61) of subjects in the vehicle group (<i>P</i> < 0.01). In Trial 2 (N = 180), treatment success was achieved in 50.5% (61/120) of subjects in the IDP-126 group versus 20.5% (12/60) of subjects in the vehicle group (<i>P</i> < 0.01). IDP-126 is therefore recommended to be applied as a thin layer to the affected area once daily.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 5","pages":"375-378"},"PeriodicalIF":0.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short Anagen Syndrome. 短促青春期综合征
Skinmed Pub Date : 2024-10-22 eCollection Date: 2024-01-01
Jonathan Young, Michaela Mifsud, Liam Mercieca
{"title":"Short Anagen Syndrome.","authors":"Jonathan Young, Michaela Mifsud, Liam Mercieca","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 10-year-old healthy, Caucasian girl presented in May 2021 with short and thin scalp hair since birth (Figures 1A-C). She had achieved all of her developmental milestones, and her parents denied any similar family history. She had only two hair cuts in the past, which were performed to trim long hair over the midscalp to have a uniform length. Hair at the front, back, and sides of the scalp were never trimmed. Examination revealed short, dark, and thin hair, varying in length from a few millimeters to 2 cm, over the frontal, parietal, and occipital areas. Longer hair were present over the midscalp, varying in length from 5 cm to 8 cm. The hairpull test was negative, and dermatoscopic examination of short hair demonstrated tapered ends, rather than cut ends. Microscopic examination revealed no hair shaft abnormality, and a trichogram of 50 parietal hair fibers demonstrated an anagen versus telogen ratio of 68:32. No associated skin, dental, or nail abnormalities were discovered.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 5","pages":"390-392"},"PeriodicalIF":0.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound Aspect of a New Hybrid Soft-Tissue Filler Combining Hyaluronic Acid and Calcium Hydroxyapatite. 一种新型混合软组织填充剂（玻尿酸与羟基磷灰石钙）的超声特性
Skinmed Pub Date : 2024-10-22 eCollection Date: 2024-01-01
Mariana Calomeni Elias, Thamires Silva Cavalcante de Almeida, Bruna Souza Felix Bravo
{"title":"Ultrasound Aspect of a New Hybrid Soft-Tissue Filler Combining Hyaluronic Acid and Calcium Hydroxyapatite.","authors":"Mariana Calomeni Elias, Thamires Silva Cavalcante de Almeida, Bruna Souza Felix Bravo","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 5","pages":"398-399"},"PeriodicalIF":0.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信